Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OKN-007 + Temozolomide in Recurrent Glioblastoma
NCT04388475Phase 2Completed
- Sponsor
- Oblato, Inc.
- Start
- Jun 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OKN-007 in glioblastoma (GBM), sponsored by Oblato, Inc.. Started Jun 2020; status: completed.
02
Drugs
OKN-007
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04388475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388475.